622 related articles for article (PubMed ID: 32221987)
1. Long-term safety, efficacy, and quality of life outcomes with adjunctive brivaracetam treatment at individualized doses in patients with epilepsy: An up to 11-year, open-label, follow-up trial.
O'Brien TJ; Borghs S; He QJ; Schulz AL; Yates S; Biton V
Epilepsia; 2020 Apr; 61(4):636-646. PubMed ID: 32221987
[TBL] [Abstract][Full Text] [Related]
2. Safety, tolerability, and efficacy of brivaracetam as adjunctive therapy in patients with focal seizures, generalized onset seizures, or Unverricht-Lundborg disease: An open-label, long-term follow-up trial.
Ben-Menachem E; Baulac M; Hong SB; Cleveland JM; Reichel C; Schulz AL; Wagener G; Brandt C
Epilepsy Res; 2021 Feb; 170():106526. PubMed ID: 33461041
[TBL] [Abstract][Full Text] [Related]
3. Adjunctive brivaracetam in adults with uncontrolled focal epilepsy: results from a double-blind, randomized, placebo-controlled trial.
Ryvlin P; Werhahn KJ; Blaszczyk B; Johnson ME; Lu S
Epilepsia; 2014 Jan; 55(1):47-56. PubMed ID: 24256083
[TBL] [Abstract][Full Text] [Related]
4. Safety, tolerability, and seizure control during long-term treatment with adjunctive brivaracetam for partial-onset seizures.
Toledo M; Whitesides J; Schiemann J; Johnson ME; Eckhardt K; McDonough B; Borghs S; Kwan P
Epilepsia; 2016 Jul; 57(7):1139-51. PubMed ID: 27265725
[TBL] [Abstract][Full Text] [Related]
5. Long-term safety and efficacy of brivaracetam in adults with focal seizures: Results from an open-label, multinational, follow-up trial.
Arnold S; Laloyaux C; Schulz AL; Elmoufti S; Yates S; Fakhoury T
Epilepsy Res; 2020 Oct; 166():106404. PubMed ID: 32731118
[TBL] [Abstract][Full Text] [Related]
6. Long-term efficacy and tolerability of adjunctive brivaracetam in adults with focal to bilateral tonic-clonic (secondary generalized) seizures: Post hoc pooled analysis.
Moseley BD; Dimova S; Elmoufti S; Laloyaux C; Asadi-Pooya AA
Epilepsy Res; 2021 Oct; 176():106694. PubMed ID: 34218211
[TBL] [Abstract][Full Text] [Related]
7. Brivaracetam as adjunctive treatment for uncontrolled partial epilepsy in adults: a phase III randomized, double-blind, placebo-controlled trial.
Biton V; Berkovic SF; Abou-Khalil B; Sperling MR; Johnson ME; Lu S
Epilepsia; 2014 Jan; 55(1):57-66. PubMed ID: 24446953
[TBL] [Abstract][Full Text] [Related]
8. Efficacy, safety, and tolerability of adjunctive brivaracetam in adult Asian patients with uncontrolled focal-onset seizures: A phase III randomized, double-blind, placebo-controlled trial.
Inoue Y; Tiamkao S; Zhou D; Cabral-Lim L; Lim KS; Lim SH; Tsai JJ; Moseley B; Wang L; Sun W; Hayakawa Y; Sasamoto H; Sano T; McClung C; Bass A
Epilepsia Open; 2024 Jun; 9(3):1007-1020. PubMed ID: 38576178
[TBL] [Abstract][Full Text] [Related]
9. Adjunctive brivaracetam for uncontrolled focal and generalized epilepsies: results of a phase III, double-blind, randomized, placebo-controlled, flexible-dose trial.
Kwan P; Trinka E; Van Paesschen W; Rektor I; Johnson ME; Lu S
Epilepsia; 2014 Jan; 55(1):38-46. PubMed ID: 24116853
[TBL] [Abstract][Full Text] [Related]
10. Retention, efficacy, tolerability, and quality of life during long-term adjunctive brivaracetam treatment by number of lifetime antiseizure medications: A post hoc analysis of phase 3 trials in adults with focal seizures.
Brandt C; Dimova S; Elmoufti S; Laloyaux C; Nondonfaz X; Klein P
Epilepsy Behav; 2023 Jan; 138():108967. PubMed ID: 36435010
[TBL] [Abstract][Full Text] [Related]
11. Long-term safety, efficacy, and quality of life during adjunctive brivaracetam treatment in patients with uncontrolled epilepsy: An open-label follow-up trial.
Toledo M; Brandt C; Quarato PP; Schulz AL; Cleveland JM; Wagener G; Klein P
Epilepsy Behav; 2021 May; 118():107897. PubMed ID: 33780735
[TBL] [Abstract][Full Text] [Related]
12. Efficacy, safety, and tolerability of adjunctive brivaracetam for secondarily generalized tonic-clonic seizures: Pooled results from three Phase III studies.
Moseley BD; Sperling MR; Asadi-Pooya AA; Diaz A; Elmouft S; Schiemann J; Whitesides J
Epilepsy Res; 2016 Nov; 127():179-185. PubMed ID: 27608437
[TBL] [Abstract][Full Text] [Related]
13. Effect of lifetime antiepileptic drug treatment history on efficacy and tolerability of adjunctive brivaracetam in adults with focal seizures: Post-hoc analysis of a randomized, placebo-controlled trial.
Klein P; McLachlan R; Foris K; Nondonfaz X; Elmoufti S; Dimova S; Brandt C
Epilepsy Res; 2020 Nov; 167():106369. PubMed ID: 32717713
[TBL] [Abstract][Full Text] [Related]
14. Long-term safety and efficacy of adjunctive brivaracetam in pediatric patients with epilepsy: An open-label, follow-up trial.
Lagae L; Klotz KA; Fogarasi A; Floricel F; Reichel C; Elshoff JP; Fleyshman S; Kang H
Epilepsia; 2023 Nov; 64(11):2934-2946. PubMed ID: 37597326
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness and tolerability of adjunctive brivaracetam in patients with focal seizures: Second interim analysis of 6-month data from a prospective observational study in Europe.
Steinhoff BJ; Christensen J; Doherty CP; Majoie M; De Backer M; Hellot S; Leunikava I; Leach JP
Epilepsy Res; 2020 Sep; 165():106329. PubMed ID: 32623096
[TBL] [Abstract][Full Text] [Related]
16. Tolerability, safety, and efficacy of adjunctive brivaracetam for focal seizures in older patients: A pooled analysis from three phase III studies.
Brodie MJ; Whitesides J; Schiemann J; D'Souza J; Johnson ME
Epilepsy Res; 2016 Nov; 127():114-118. PubMed ID: 27589414
[TBL] [Abstract][Full Text] [Related]
17. Efficacy, safety, and tolerability of brivaracetam with concomitant lamotrigine or concomitant topiramate in pooled Phase III randomized, double-blind trials: A post-hoc analysis.
Benbadis S; Klein P; Schiemann J; Diaz A; Elmoufti S; Whitesides J
Epilepsy Behav; 2018 Mar; 80():129-134. PubMed ID: 29414542
[TBL] [Abstract][Full Text] [Related]
18. Safety and tolerability of adjunctive brivaracetam in epilepsy: In-depth pooled analysis.
Brandt C; Klein P; Badalamenti V; Gasalla T; Whitesides J
Epilepsy Behav; 2020 Feb; 103(Pt A):106864. PubMed ID: 31937513
[TBL] [Abstract][Full Text] [Related]
19. Final safety, tolerability, and seizure outcomes in patients with focal epilepsy treated with adjunctive perampanel for up to 4 years in an open-label extension of phase III randomized trials: Study 307.
Krauss GL; Perucca E; Kwan P; Ben-Menachem E; Wang XF; Shih JJ; Patten A; Yang H; Williams B; Laurenza A
Epilepsia; 2018 Apr; 59(4):866-876. PubMed ID: 29574701
[TBL] [Abstract][Full Text] [Related]
20. Safety and tolerability of adjunctive brivaracetam in children with focal seizures: Interim analysis of pooled data from two open-label trials.
Patel AD; Badalamenti V; Gasalla T; Elmoufti S; Elshoff JP
Eur J Paediatr Neurol; 2020 Mar; 25():68-76. PubMed ID: 31810577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]